Trillium Therapeutics (TRIL) Commences Dosing in TTI-621 Phase 1
Tweet Send to a Friend
Trillium Therapeutics Inc. (Nasdaq: TRIL) announced that it has initiated dosing in its Phase 1 clinical trial of TTI-621 (SIRPaFc) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
